Experiences with

Jakavi

Hello, I hope one of the experts or doctors can answer this question. I have PV & MF and taking Jakafi 25mg twice daily. I had to go to another oncologist recently who said my counts looked good so I was in a type of remission and now I'm just nyloproliferative disorder. But she said to keep taking

The SMC have announced this month that they have approved Ruxolitinib (Jakavi) for the treatment of MF, and therefore this medication can now be prescribed to patients via NHS Scotland, it has previously only been available to patients after a specific individual application for exceptional funding

Hi Guys, as some of you will be aware I have been having an uphill struggle to be put onto Ruxolitinib. Well Im pleased to say the day has finally arrived. And as you may also recall I have my own way of recording such milestones so I have penned a few lines to share my experience of it with you. And

We need your help and feedback to support an application to the Scottish Medicines Consortium (SMC) for the prescribing of Ruxolitinib (Jakavi) to patients living in Scotland Ruxolitinib (Jakavi) as a treatment for disease related splenomegaly (enlarged spleen) or symptoms in adults with primary myelofibrosis

Novartis Pharmaceuticals UK Limited have informed MPD Voice that as of Friday 16th August 2013, Jakavi (Ruxolitinib) tablets will be packaged in blister packs, the formulation of the tablets will remain the same, it is just the packaging that has changed.

Further to the NICE draft guidance not recommending Ruxolitinib (Jakavi, Novartis), for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adults with primary myelofibrosis, or myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia.